Astellas stock symbol is TLV, listed on the Tokyo Stock Exchange under the ticker code 4503.
Astellas Pharmaceuticals is a Japanese multinational pharmaceutical company.
The company's stock has shown a steady performance over the years, with a significant increase in its market value.
Astellas has been paying dividends to its shareholders since 1996.
Additional reading: Brcc Stock Symbol
Stock Performance
Astellas stock has seen a significant increase in revenue in 2023, reaching 1.60 trillion, up 5.60% from the previous year's 1.52 trillion.
This growth is notable, and it's worth noting that the company's revenue has consistently shown an upward trend in recent years.
However, the company's earnings took a hit, decreasing by -82.73% to 17.05 billion in 2023.
Today's Stock Price
The Astellas Pharma stock price is 9.380 USD today. This is a significant figure for investors looking to make informed decisions about their portfolio.
As we track the Astellas Pharma stock performance, it's clear that the current price is a notable one.
On a similar theme: Stock Price
Will Stock Price Drop?
The stock market can be unpredictable, but sometimes we can get a glimpse into what's to come. The Astellas Pharma stock price may drop from 9.380 USD to 8.236 USD.
A 12.197% decrease is a significant drop, and it's essential to consider this when making investment decisions. This change could have a substantial impact on your portfolio.
Investors should be aware that stock prices can fluctuate rapidly, and it's crucial to stay informed to make the best decisions. The Astellas Pharma stock price may drop from 9.380 USD to 8.236 USD.
A 12.197% decrease is a significant drop, and it's essential to consider this when making investment decisions.
Growth Rank
The Growth Rank section of a stock's performance is a crucial indicator of its overall health. It shows how a company's growth rates compare to its industry and historical performance.
The 3-Year Revenue Growth Rate is a key metric here, and in this case, it's a respectable 9.8%. This means the company has been steadily increasing its revenue over the past three years.
A growth rate of 9.8% is actually above the industry average, indicating that this company is performing better than its peers. However, it's worth noting that revenue growth is just one aspect of a company's overall health.
On the other hand, the 3-Year EPS without NRI Growth Rate is a concerning -55.4%. This suggests that the company's earnings per share have been declining over the past three years, which could be a red flag for investors.
Here's a breakdown of the company's growth rates over the past three years:
It's worth noting that the company's future growth estimates are still quite high, with a predicted 3-5 year EPS without NRI growth rate of 163.22% and a 3-5 year total revenue growth rate estimate of 6.96%.
Dividend & Buy Back
The "Dividend & Buy Back" section of a stock's performance is a crucial aspect to consider when evaluating its overall health.
Dividend Yield is a key metric, and in this case, it's 5.05%. This means that for every dollar invested, you can expect to earn 5.05 cents in dividend payments per year.
The company's Dividend Payout Ratio is a relatively low 2.36, indicating that it's not breaking the bank to pay out dividends to shareholders.
A 3-Year Dividend Growth Rate of 18.6% is impressive, showing a consistent increase in dividend payments over time.
The Forward Dividend Yield is also 5.05%, indicating that the company is committed to maintaining its current dividend payout.
Share Buybacks can also be a sign of a company's confidence in its future prospects, with a 3-Year Average Share Buyback Ratio of 1.1.
However, the Shareholder Yield is a negative -9.06%, suggesting that the company is not currently returning value to shareholders through buybacks or dividends.
Key Statistics
The Key Statistics section provides valuable information about a company's performance.
Revenue(TTM) stands at a significant $12,363.604 million, indicating a substantial revenue stream.
EPS(TTM) is currently at -$0.206, suggesting a loss per share.
Beta measures a stock's volatility, and in this case, it's a relatively low 0.24, indicating a stable investment.
A 3-Year Sharpe Ratio of -0.85 and 3-Year Sortino Ratio of -1.08 suggest that the stock has underperformed in terms of risk-adjusted returns.
The stock's volatility is 28.19%, which is higher than average, indicating a riskier investment.
The 14-Day RSI is at 38.12, which is below the neutral threshold of 50, indicating that the stock may be undervalued.
The 20-Day SMA is $9.57462, which is a good indicator of the stock's short-term trend.
A 12-1 Month Momentum of -12.18% suggests that the stock has been trending downwards over the past year.
The 52-Week Range is between $9.05 and $13.14, indicating a significant price fluctuation over the past year.
Shares Outstanding total 1,790.12 million, giving you an idea of the stock's liquidity.
A unique perspective: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically
Frequently Asked Questions
Is Astellas Pharma a buy?
Astellas Pharma (ALPMY) is currently considered a buy by Zacks, with a #2 (Buy) rank and A Value grade. This suggests strong potential for investors, but further research is recommended for a more informed decision.
What is the net worth of Astellas Pharma?
Astellas Pharma's net worth is approximately $17.66 billion as of December 2024. This figure represents a decrease of 18.81% from its market value a year prior.
Featured Images: pexels.com
